spacer
home > epc > autumn 2018 > quality compliance
PUBLICATIONS
European Pharmaceutical Contractor

Quality Compliance

Clinical and manufacturing departments tend to view quality and compliance from different perspectives because they are each focussed on different sets of compliance requirements (or perhaps the industry has become conditioned to seeing them as distinct on a perfunctory level). However, both groups can streamline compliance and increase effectiveness by applying many of the same quality practices to their compliance efforts. The core ideologies that form the basis of quality best practices are universal principles that apply not only to Good Manufacturing Practice (GMP) but to Good Clinical Practice (GCP) as well.

Intersections in Compliance Requirements

Clinical and manufacturing compliance efforts overlap in several comparable areas:

Deviations
Just as deviations in manufacturing are indicative of poor product quality, the lack of protocol adherence and inconsistencies in protocol implementation are signifiers of quality deficiencies in clinical trials. Since the study protocol is the single most important document in a clinical trial, adherence to the protocol is essential if quality is to be maintained. Correspondingly, strict observance of production standard operating procedures (SOPs) in manufacturing is critical to effective quality management. Parallel to an effective quality management system’s (QMS) criticality to deviation management in manufacturing, a systematised approach to clinical quality that emphasises clinical quality management principles can refine the focus on events that occur across studies and product lines and help manage actiontaking once a deviation issue has been identified. Always keep in mind that many deviation management principles can be applied in both manufacturing and clinical scenarios, such as identifying the source of an issue, identifying any areas that may be impacted, and using universal problemsolving techniques to conduct root cause analyses (ie, fishbone diagrams, the ‘5 Whys’ technique, etc).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Patricia Santos-Serrao, MasterControl’s Director of Clinical and Regulatory Solutions, started her life sciences career in 1994 with Schering-Plough and later joined Boehringer Ingelheim Pharmaceutical. Within both organisations, Patricia took a leading role in transitioning business processes, document management, and submission compilation from paper to electronic systems. She is a member of Regulatory Affairs Professional Society (RAPS) and earned her Regulatory Affairs Certification from RAPS and the Regulatory Affairs Certification Board. Patricia is a member of the Drug Information Association (DIA) and a member of the DIA-sponsored Trial Master File Reference Model working group.
spacer
Patricia Santos-Serrao
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Protagen Protein Services (PPS) reaches new level in characterizing HCP protein impurities

In response to current regulatory guidance a Mass Spectrometry (MS) based Host Cell Protein (HCP) detection approach with faster, more accurate and wider-ranging detection is essential. In order to meet the newly prevailing demands Protagen Protein Services (PPS) recently invested in more far-reaching MS capabilities: The new high-performing mass spectrometer ThermoFisher Q Exactive™ HF-X started operational service last month and brings PPS to the next level of reproducible, accurate and sensitive analyses of majorly complex samples for different aspects of translational research and biopharma applications.
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement